New Oral Compound SM-130686 Potently Boosts Growth Hormone in Rats
Background
Growth hormone (GH) plays a crucial role in metabolism, growth, and body composition. Growth hormone secretagogues (GHSs) are compounds that stimulate the body's natural release of GH, offering therapeutic potential for conditions like GH deficiency, frailty, and muscle wasting. Current GHSs often require injections or have limited oral bioavailability, creating a significant need for effective, orally active compounds.
Results
In vitro, SM-130686 demonstrated high affinity for GHSR-1a, with a Ki value of 2.5 nM, and stimulated GH release from rat pituitary cells with an EC50 of 12 nM. The compound exhibited excellent oral bioavailability, with peak plasma concentrations observed within 60 minutes post-dosing. > The most significant finding was the robust, dose-dependent increase in plasma GH levels in rats, with the 1.0 mg/kg dose leading to a 4.3-fold increase in peak GH compared to controls on day 1, and a sustained 3.8-fold increase on day 14. The 0.3 mg/kg dose showed a 2.7-fold increase in GH, while the 0.1 mg/kg dose resulted in a 1.5-fold increase (p<0.001 for all treated groups vs. control). Importantly, SM-130686 did not significantly alter prolactin or ACTH levels, indicating selectivity for GH release. Furthermore, treated animals exhibited a 15% increase in lean body mass over 14 days compared to controls (p<0.05).
Why It Matters
This study highlights SM-130686 as a potent, selective, and orally active growth hormone secretagogue. Its ability to significantly boost GH levels and improve lean body mass in an animal model suggests considerable therapeutic potential. This compound could represent a breakthrough for treating conditions like age-related sarcopenia (muscle loss), GH deficiency in adults, or cachexia (wasting syndrome) in chronic diseases. Further development, including human clinical trials, is warranted to explore its efficacy and safety in patients.